Profile data is unavailable for this security.
About the company
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
- Revenue in SEK (TTM)104.24m
- Net income in SEK-196.45m
- Incorporated2005
- Employees29.00
- LocationVicore Pharma Holding ABKornhamnstorg 53STOCKHOLM 111 27SwedenSWE
- Phone+46 317880560
- Websitehttps://vicorepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanoform Finland Oyj | 26.56m | -250.84m | 1.12bn | 174.00 | -- | 1.36 | -- | 42.05 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Diamyd Medical AB | 130.00k | -151.85m | 1.30bn | 27.00 | -- | 8.77 | -- | 9,985.54 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.17 | 4,814.82 | -71.82 | -34.32 | -83.67 | -38.45 | -10,161.54 | -3,111.20 | -116,806.90 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.39bn | 5.00 | -- | 5.49 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Solar Foods Oyj | 200.52k | -123.76m | 1.43bn | 40.00 | -- | 4.36 | -- | 7,113.47 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
| Nightingale Health Oyj | 50.45m | -202.17m | 1.43bn | 86.00 | -- | 2.23 | -- | 28.29 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.05m | 1.60bn | 24.00 | -- | 2.52 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vicore Pharma Holding AB | 104.24m | -196.45m | 1.88bn | 29.00 | -- | 2.37 | -- | 18.05 | -1.72 | -1.72 | 0.9135 | 3.38 | 0.2045 | -- | 43.73 | 4,343,459.00 | -38.54 | -58.65 | -41.49 | -65.58 | -- | -- | -188.45 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 79.20m | -295.80m | 1.94bn | 33.00 | -- | 4.96 | -- | 24.49 | -1.07 | -1.07 | 0.2882 | 1.09 | 0.1425 | 23.00 | 3.61 | 2,933,333.00 | -48.67 | -33.02 | -61.23 | -36.46 | 85.48 | -- | -341.54 | -357.72 | 0.9808 | -19.71 | 0.2605 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Hansa Biopharma AB | 189.39m | -654.78m | 2.05bn | 135.00 | -- | -- | -- | 10.82 | -11.34 | -11.34 | 3.21 | -4.72 | 0.1794 | 34.61 | 1.25 | 1,127,321.00 | -62.01 | -47.96 | -86.68 | -56.12 | 53.43 | 64.18 | -345.73 | -835.04 | 2.44 | -41.44 | 1.50 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Devyser Diagnostics AB | 198.00m | -71.40m | 2.28bn | 119.00 | -- | 6.52 | -- | 11.51 | -4.37 | -4.37 | 12.12 | 21.17 | 0.4019 | 1.97 | 5.29 | 1,677,966.00 | -14.51 | -8.97 | -16.40 | -10.15 | 80.00 | 80.14 | -36.11 | -23.91 | 3.81 | -- | 0.1492 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Data as of Nov 13 2024. Currency figures normalised to Vicore Pharma Holding AB's reporting currency: Swedish Krona SEK
16.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 11.26m | 5.04% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 11.18m | 5.00% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Dec 2023 | 3.44m | 1.54% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2023 | 3.44m | 1.54% |
| Swedbank Robur Fonder ABas of 31 Dec 2023 | 2.47m | 1.11% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 2.32m | 1.04% |
| Medical Strategy GmbHas of 31 May 2023 | 1.16m | 0.52% |
| SEB Investment Management ABas of 30 Sep 2024 | 1.10m | 0.49% |
| Andra AP-fondenas of 31 Dec 2023 | 543.44k | 0.24% |
| FCG Fonder ABas of 30 Sep 2024 | 381.78k | 0.17% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
